Anti-NAC1, clone 9.27

Anti-NAC1, clone 9.27, Cat. No. MABC1713, is a mouse monoclonal antibody that detects Nucleus accumbens-associated protein 1 (NAC1) and has been tested for use in ELISA, Immunocytochemistry, Immunohistochemistry (Paraffin) and Western Blotting.

ELISA Immunocytochemistry Immunohistochemistry (Paraffin) Western Blotting

Immunohistochemistry (Paraffin) Analysis: A 1:250 dilution from a representative lot detected NAC1 in human ovarian cancer tissue sections.

Immunohistochemistry (Paraffin) Analysis: A representative lot detected NAC1 in Immunohistochemistry applications (Okazaki, K., et. al. (2012), Carcinogenesis. 33(10):1854-62).

Western Blotting Analysis: A representative lot detected NAC1 in Western Blotting applications (Okazaki, K., et. al. (2012), Carcinogenesis. 33(10):1854-62).

Enzyme Immunoassay Analysis: A representative lot detected NAC1 in ELISA applications (Okazaki, K., et. al. (2012), Carcinogenesis. 33(10):1854-62).

Immunocytochemistry Analysis: A representative lot detected NAC1 in Immunocytochemistry applications (Okazaki, K., et. al. (2012), Carcinogenesis. 33(10):1854-62).

Clone 9.27 is a mouse monoclonal antibody that detects Nucleus accumbens-associated protein 1 (NAC-1).

GST-tagged full-length recombinant human NAC-1 protein.

Stable for 1 year at 2-8°C from date of receipt.

Purified mouse monoclonal antibody IgG1 in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Evaluated by Immunohistochemistry (Paraffin) in human colon tissue sections.

Immunohistochemistry (Paraffin) Analysis: A 1:50 dilution of this antibody detected NAC1 in human colon tissue sections.

Nucleus accumbens-associated protein 1 (UniProt: Q96RE7; also known as NAC-1, BTB/POZ domain-containing protein 14B) is encoded by the NACC1 (also known as BTBD14B, NAC1) gene (Gene ID: 112939) in human. NAC-1 serves as a transcriptional repressor in neuronal cells through the recruitment of HDAC3 and HDAC4. It contains a BTB domain (aa 30-94; Broad Complex, Tramtrack and Bric à brac) at its N-terminal and a BEN domain (aa 374-471; BANP, E5R and NAC1) in its C-terminal region. NAC1 undergoes homodimerization through its BTB domain. It differs from other BTB-domain transcription factors in that it lacks a characteristic zinc finger or basic leucine-zipper DNA-binding domain. NAC-1 is shown to be important in maintaining pluripotency of embryonic stem cells. It can direct bind to Nanog and also regulates the expression of Nanog, Oct4, and Sox-2. NAC-1 is reported to be overexpressed in several types of human carcinomas, including ovarian serous, pancreatic, and breast carcinoma. It contributes to tumor progression, tumor cell proliferation, and survival through repressing transcriptional activity of GADD45GIP1. NAC-1 knock-down can result in the apoptosis of ovarian cancer cell lines and enhance their chemosensitivity. (Ref.: Okazaki, K., et al. (2012). Carcinogenesis. 33(10); 1854 1862; Nakayama, N., et al. (2018). Oncotarget. 9(47); 28408-28420).

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.